KRAS and cancer: Mitochondrial fission driven by activating phosphorylation of DRP1 (pDRP1S616) downstream of both KRAS or BRAF pathway/s confers a growth advantage as well as metabolic shift towards a more glycolytic phenotype in various models of cancer (34, 50).